EU Approval Decision Delay For BMS’s Ozanimod

Company Needed More Time To Answer Questions On New MS Product

BMS should find out mid-2020 whether its new MS drug will be approved in the EU.

Question marks
Companies sometime ask for extra time to address regulators' questions • Source: Shutterstock

More from Europe

More from Geography